AMERICAN ACADEMIC PUBLISHER

INTERNATIONAL JOURNAL OF MEDICAL SCIENCES

ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

THE RELEVANCE OF IMPROVING MEASURES FOR SCREENING AND PRESERVING STRAINS OF MICROBIOLOGICAL TESTS

Nargiza Rakhimova Rustamdzhanovna
Assistant of the Department of Allergology, Clinical Immunology, and Microbiology of Tashkent State Medical University
e-mail: nargizka.raximova89@gmail.com

Abstract. Antibiotics, vaccines, and medications for a variety of illnesses are made from a variety of microorganisms; by keeping these microbes and viruses alive, the creation process can be expedited. We have examined new and developing technologies as well as both short-term and long-term microbial and viral preservation techniques. The goal of short-term microbe preservation techniques is to keep the organisms viable for a few days to a year. A major worldwide concern is infectious diseases, which are made worse by the rise of antibiotic resistance. As a result, scientists are looking at new antibacterial substances as possible remedies. The significance of the techniques used for screening and assessing antimicrobial activity—a crucial stage in the identification and characterization of antimicrobial agents—is highlighted by this work. Traditional methods including broth-dilution, disk-diffusion, and well-diffusion are frequently used in antimicrobial studies, although their speed and repeatability may be limited. Antimicrobial evaluations also frequently use a wide range of antimicrobial tests, such as cross-streaking, poisoned-food, co-culture, time-kill kinetics, resazurin assay, bioautography, etc. Advanced methods including bioluminescence, flow-cytometry, and impedance analysis may provide sensitive and quick results, giving more information about how antimicrobials affect cellular integrity. Nonetheless, there can be difficulties due to their greater expense and restricted availability in specific lab environments. This page gives a thorough rundown of assays used to describe antibiotic activity, explaining their fundamental ideas, procedures, benefits, and drawbacks. In our never-ending fight against infectious diseases, the main goal is to improve knowledge of the techniques created for assessing antimicrobial agents. Researchers can identify favorable conditions and expedite the identification of potent antimicrobial drugs by choosing the best antimicrobial testing technique.

Keywords. Time kill kinetics, broth dilution, resazurin test, disk diffusion test, co-culture assay, antimicrobial assay technique, antimicrobial susceptibility testing.

Introduction. As infectious diseases become more difficult to cure, antimicrobial resistance (AMR) is a major global concern. The problem is made much more difficult by the rise in multi-resistant bacteria and the slow development of new antimicrobials. Researchers are investigating both synthetic and natural antibacterial substances as possible remedies to this problem. Natural products that come from bacteria, plants, and animals are a great source of biologically active substances that may be useful in the fight against illnesses. Furthermore, laboratory-created synthetic antibacterial agents have shown incredible promise in the fight against microbial diseases. Appropriate antimicrobial screening and evaluation techniques are crucial to maximizing these compounds' potential. Because they offer vital information about the efficacy and mechanisms of action of novel antimicrobial drugs, in vitro antimicrobial tests are essential to their discovery and development. Gaining a better understanding of these techniques would aid researchers in more effectively identifying possible antibiotic candidates and assist combat the growing threat of AMR [1-6]. Despite their widespread use, conventional procedures such as

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

broth dilution techniques and disk diffusion may have time and repeatability issues. However, more recent techniques like flow cytometry, bioluminescence, and impedance measurement provide more sensitivity and throughput, but they could be more expensive and difficult to use in areas with limited resources. In the sterile manufacture of pharmaceuticals, bioburden and sterility assurance are important considerations. There can be major health dangers if unexpected bioburden levels in pharmaceutical manufacture are not controlled. These hazards range from serious side effects to potentially fatal illnesses. For example, non-sterile parenteral can introduce systemic bloodstream infections that lead to bacteremia or septicemia, or septic shock if endotoxin contamination is involved; contaminated ophthalmic solutions can cause endophthalmitis and vision loss hazards. To guarantee the sterility of such items, strict adherence to the legal requirements of aseptic processing techniques, good manufacturing practices (GMP), and sterilization is essential. Microbial contamination is still an issue in the sterile production of pharmaceutical products, despite the implementation of standards and guiding rules [7-12]. Aside from the negative health effects, failing to maintain sterility results in product recalls, which are expensive for producers and healthcare providers. The majority of the recalled medications were caused by a lack of sterility, according to data from published publications. The production environment, the manufacturing process, and raw materials, such as pharmaceutical water, are the main sources of microbial contamination in sterile manufacture, according to the majority of reported cases. The application of aseptic production, GMP, and bioburden management is anticipated to result in unpredictable high bioburden levels. However, sterilization or aseptic processing should be used to keep the bioburden on the final sterile product within acceptable bounds. To protect consumers, it is frequently necessary to identify contaminating microorganisms and estimate the severity of the bioburden. Unexpectedly large concentrations of pathogenic or non-pathogenic organisms during the production process are unacceptable and must be addressed right away in sterile goods, such as parenteral and ophthalmic preparations. The final product must be sterile since aseptic processing, sterile filtering, or terminal sterilization are methods used to manage the removal of bioburden obtained during the manufacturing process [13-19]. Therefore, it is crucial to conduct a thorough analysis of the *in vitro* tests that are employed to evaluate the antibacterial properties of both natural and artificial substances. An overview of the most used in vitro tests for determining the antibacterial activity of prospective synthetic and natural substances is given in this paper. Time-kill kinetics, flow cytometry, bioluminescence assay, impedance measurement, agar dilution, broth macrodilution and microdilution, resazurin assay, co-culture method, disk diffusion assay, well diffusion, spot assay, cross-streaking method, and poisoned food method are among the techniques discussed. The benefits and drawbacks of each assay are discussed, covering topics such as cost, accessibility, repeatability, sample complexity, and other pertinent considerations. In order to effectively identify prospective antimicrobial agents and contribute to the development of effective medicines against infectious diseases, this thorough overview attempts to assist researchers and practitioners in selecting suitable screening approaches [20-29]. The study urges researchers to investigate strategies and technologies that improve the precision, sensitivity, and effectiveness of antimicrobial detection by outlining the shortcomings and gaps in existing methodology. This review introduces the traditional growth-based bioburden and sterility test methodologies and gives background information on microbial contamination of medications. The limits of growth-based microbiological techniques for bioburden and sterility tests in pharmaceutical manufacturing are also covered in the review, which contrasts them with the benefits of quick microbial detection techniques in terms of accuracy, specificity, and time to results [30-38].

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

The main purpose of the presented manuscript is a brief commentary on the results of reputable scientific papers on the relevance of improving screening measures and preserving microbiological test strains.

Bioburden testing sample. Samples of bioburden are collected from the expected sources of contamination, including raw materials, the manufacturing process, the production environment, humans, and water. Regulatory agencies like the FDA and European Medicines Agency (EMA) offer detailed instructions on product batch sampling for bioburden management and sterility testing. For instance, at the conclusion of the procedure, pharmaceutical samples need to be taken aseptically in a sterile container. The suggested sample size and sampling techniques are included in the sampling plans. USP < 1116 > identifies the key sample locations, which are mostly close to areas with a high bioburden that may be anticipated, such as those near exposed products, closures, and containers, difficult-to-clean locations, or traffic areas where microbes can spread. Other microbiological tests are used by environmental monitoring programs to track the bioburden of air, surfaces, operators, and equipment in order to further evaluate the effects of microbial contamination from the manufacturing environment on the final product. These tests consist of contact plates, swabs, finger plates, settle plates, and air samples. the fundamental bioburden environmental monitoring techniques used in manufacturing, together with their benefits and drawbacks [3-11].

Current techniques for checking for microbiological contamination. monitoring of bioburden in sterile production. The total aerobic microbial count (TAMC) and total combination yeast and mold count (TYMC) of a product are referred to as bioburden in the Pharmacopeial definition. The bioburden test is frequently conducted for each batch of sterile and non-sterile items, and the bioburden count is expressed in CFUs. As a control measure before final filtering or sterilization, the bioburden count is required for sterile products, such as medications that are aseptically filled or filtered and single-use items. Bioburden testing offers important information for assessing the microbiological quality of the product in sterile manufacture [5-10]. As a result, it is used in environmental monitoring programs and at various stages of the production process to assess the microbial load of incoming raw materials or new products. While non-routine monitoring is used to confirm results in the event of bioburden deviation, routine environmental monitoring involves bioburden testing on designated regions on a schedule. Environmental monitoring data is useful for making adjustments and preventing product contamination. The bioburden data, which includes the number and type of viable aerobic microorganisms, is helpful in guiding the maker in non-sterile manufacturing when a particular microbial load exceeds the limit or when there is an undesirable bacterial growth. Monitoring of bioburden may reveal the underlying source of contamination. Every production batch regularly undergoes sampling for bioburden testing at different phases, from raw materials to finished goods, particularly for aseptically processed and non-terminally sterilized products [17-24].

Growth-based bioburden and sterility test challenges. ***Distribution of microbiological contamination and sampling.*** For many reasons, it is insufficient to perform sterility and bioburden tests as the sole methods to verify the lack of contaminant bacteria in order to detect all contamination episodes. Since the likelihood of bioburden detection depends on sample size and the actual percentage of contaminated items in the batch, the standards' sampling procedures for bioburden monitoring or sample size are insufficient to provide enough information in monitoring of all potential risk points relevant to the product's microbiological quality. For example, the sample size as determined by the pharmacopeia for a batch of over 500 filled container items is only 20 samples, which is far beyond to provide statistical confidence in sterility assurance of the produced batch. Second, a non-uniform distribution of microbial

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

contamination can result in false-negative test findings, which may be assumed to be caused by either test settings that are incompatible with microbial growth or the use of non-contaminated samples. When bacteria adapt to the product formulation and multiply during storage, tainted samples of the same batch are discovered after distribution. Consequently, random sampling by itself is insufficient for precise contamination identification in a manufactured batch. The type and distribution of microorganisms are also greatly influenced by factors including the aseptic environment's stress conditions and disinfectant residues on processing surfaces, which cause some pathogenic and saprophytic bacteria to go into a latent, non-cultivable state [31-42].

In order to overcome the difficulties of decreasing the duration of traditional testing and improving sensitivity to microbial detection, rapid microbiological techniques (RMMs) were created for the prompt identification of microbial contamination. As automated devices, RMMs have a great potential to enhance microbiological quality control. Both growth-dependent and growth-independent techniques, which are included in RMMs, are useful for identifying and measuring microbial pollutants. Growth-based techniques measure physiological or chemical growth characteristics to identify and measure only proliferative organisms on solid or liquid medium [27-34]. Non-growth-based techniques make use of technologies including mass spectrometry, flow cytometry, growth metabolic byproducts, nucleic acid-based techniques, and others. These techniques can also be categorized as quantitative (which gives a numerical result of the microbial content) and qualitative (which evaluates the microbiological quality as the absence of microorganisms). Notably, the qualitative category result of "no growth detected" does not necessarily indicate that there are no bacteria present at all. Under the test parameters used, no growth was seen, according to the present compendia. Consequently, when selecting the candidate RMM technique, the intrinsic analytical dogma of the compendial methods should be taken into account. Furthermore, regulatory evaluation is necessary to guarantee the accuracy and reproducibility of the data collected. Nonetheless, EP and USP promote the usage of RMMs and their applications. Some international corporations have received permission for quick sterility testing from the Japanese Pharmaceuticals and Medical Device Agency (PMDA), the FDA, the European Medicines Agency (EMA), or the Medicines and Healthcare Products Regulatory Agency (MHRA). For certain applications, manufacturers can select from a variety of RMM systems [35-43].

Looking ahead. The identification of contaminants in pharmaceutical products has been demonstrated to be inadequate when relying solely on sterility testing and complex compendial bioburden. The development of new treatments in the modern era, which must crucially have an adequate degree of sterility assurance, may be slowed down if standards and regulations continue to need these antiquated test procedures. Current sterility assurance laws may have an impact on market availability and hinder the quick uptake of cutting-edge pharmaceuticals. With high specificity and accuracy, RMMs can rapidly detect and measure microbiological or product bioburden hazards as part of contamination control plans [30-35]. The qualities of RMMs surpass those of growth-based techniques and have the potential to enhance sterility assurance in the future. However, an integrated component strategy that incorporates all available sterility assurance methods is encouraged in order to boost trust in a product's safety or sterility. On the one hand, this can be accomplished by putting in place an integrated system that consists of applied quality systems and environmental monitoring data collected through surface, air, water, and human samples on the frequency of contamination and the quantity of microorganisms in the process. However, to address current sterility assurance issues, enhancements must be made simultaneously. A paradigm shift in sterility verification is necessary, which includes a move

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

toward risk management, the use of RMMs, and the introduction of process automation to minimize human involvement [36-43].

Discussion. Patients are harmed by nonsterile parenteral products, which leads to major public health problems and significant financial losses for pharmaceutical companies. A contamination program should be implemented to guarantee product sterility in order to prevent such outcomes. This can involve routine sterility testing and bioburden assessment. It has been stated that the existing compendial recommendations for bioburden and sterility testing do not adequately verify the complete absence of microorganisms through the use of traditional growth-based microbiological methods alone. The purpose of this review was to examine the benefits and limitations of the current conventional and quick microbiological detection techniques. To describe the microbiological contamination in the sterile manufacturing of pharmaceuticals, a comprehensive assessment of the literature was carried out. A summary of the drawbacks and restrictions of the conventional growth-based techniques for sterility testing and bioburden evaluation was given [6-13]. The current standard technology in the production of sterile pharmaceuticals is the traditional growth-based bioburden and sterility testing procedures. Rapid microbiological detection techniques, on the other hand, offer extremely sensitive systems that may quickly confirm the absence of microbial pollutants, even those with very low microbial counts, which may surpass the advantages of growth-based techniques. The use of quick microbiological detection techniques ought to be reexamined as a potential obstacle to enhancing pharmaceutical product sterility assurance. However, due to constraints including high costs, knowledge, test validation costs, and regulatory limitations, their usage in the large-scale production of pharmaceutical goods may continue to lag. Growth-based microbiological techniques by itself cannot conclusively ascertain the complete absence of live microorganisms, according to the research reviewed here. Only approaches that use the methodology outlined in the current compendial standards for bioburden estimate are regarded as estimation methods that accurately reflect the microbiological quality of pharmaceutical manufacture. Erroneous conclusions regarding microbial limits and the lack of substantial sources of bioburden in the manufacturing process can arise from sample restrictions, testing inaccuracy, test-to-result time, and inefficiencies in microbial detection [18-26]. These conclusions can have negative health and economical effects. RMMs, on the other hand, can offer a very sensitive technology that can be used to confirm that microbiological contaminants are not present in a wide range of samples. In a brief amount of time, it may also confirm that the examined samples are free of VBNC, microbiological contamination, and trace amounts of microbial pollutants. Adopting RMMs to improve sterility assurance will be a future challenge for pharmaceutical makers as these techniques advance. This study finished screening and identifying the improved microorganisms and their impact on the quality of Baijiu. It also offered a guide for enhancing the functional quality of Baijiu by bioaugmentation. For additional interpretation, future research should concentrate on clarifying how improved strains affect the fermentation system, particularly the dynamic shifts in the physicochemical indexes and the composition of the fermented grains' microbial community [38-43].

Conclusion. As researchers look for new and powerful antimicrobial drugs to fight infectious diseases, antimicrobial research is expanding remarkably. The pressing need to address antibiotic resistance and its effects on global health is driving this research boom. In this endeavor, ongoing attempts are being made to create modern, effective techniques that can successfully detect and assess these possible antimicrobial compounds. However, no single technique can be considered the best by everyone because several aspects including sample size,

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

equipment availability, and the type of agents being evaluated affect the methodology that is used.

To expedite the antimicrobial screening process, researchers are progressively choosing less time-consuming, automated, quicker, and easier-to-use techniques. Although cutting-edge technologies like high-throughput sequencing and sophisticated microscopy have the potential to be used to analyze the precise characteristics and mechanisms of action of antimicrobial drugs, their widespread use and effectiveness in antimicrobial assays have not yet been completely realized. To improve the precision and dependability of antimicrobial screening, attempts are being made to integrate several approaches or supplement current ones. For reliable and consistent outcomes, both automatic and human methods must be updated and improved on a regular basis.

An appropriate balance between simplicity and sensitivity in the test methods can be reached by researchers by customizing method choices to particular requirements and refining current procedures accordingly. In the end, the creation and discovery of potent antimicrobial agents could greatly benefit from the use and improvement of these antimicrobial testing techniques. By strengthening the fight against the growing threat of antimicrobial resistance and improving the management of infectious diseases, this advancement helps to protect public health globally.

References.

1. Hossain TJ. Methods for screening and evaluation of antimicrobial activity: A review of protocols, advantages, and limitations. Eur J Microbiol Immunol (Bp). 2024 Apr 22;14(2):97-115. doi: 10.1556/1886.2024.00035.
2. Senaratne WMTN, Jayaweera JAAS. Comparison of Microbial Preservation Methods: A Narrative Review. Germs. 2024; 14(4):375-386. https://doi.org/10.18683/germs.2024.1447
3. Hou, K., Wu, ZX., Chen, XY. et al. Microbiota in health and diseases. Sig Transduct Target Ther 7, 135 (2022). https://doi.org/10.1038/s41392-022-00974-4
4. Aripov A.N., Aripov O.A., Akhundjanova L.L., Nabiev A.U., Nabieva D.A., & Khamroev T.T. (2022). Study the effect of yantacin on some indicators of cellular renewal and on the level of protein expression on rat hepatocytes in chronic heliotrine liver damage. International Journal of Medical Sciences And Clinical Research, 2(05), 06–13. https://doi.org/10.37547/ijmscr/Volume02Issue05-02.
5. Chojnacki, C.; Konrad, P.; Błońska, A.; Medrek-Socha, M.; Przybylowska-Sygut, K.; Chojnacki, J.; Poplawski, T. Altered Tryptophan Metabolism on the Kynurenine Pathway in Depressive Patients with Small Intestinal Bacterial Overgrowth. Nutrients 2022, 14, 3217.
6. Aripov A. N, Akhunzhanova L. L, Nabiev A. U, Aripov A. O, Khamroev T. T.. Antifibrotic Efficacy of a New Phytocomposition of Essential Phospholipids with Glycyrrhizic Acid, Ecdysterone, Lycopene and Proanthacyanidin in Experimental Severe Chronic Hepatitis Compared with Phosphogliv. Biomed Pharmacol J 2023;16(3).Pages : 1815-1825. DOI : https://dx.doi.org/10.13005/bpj/2761
7. Socała K., Doboszewska U., Szopa A., Serefko A., Włodarczyk M., Zielińska A., Poleszak E., Fichna J., Wlaź P. The Role of Microbiota-Gut-Brain Axis in Neuropsychiatric and Neurological Disorders. Pharmacol. Res. 2021;172:105840. doi: 10.1016/j.phrs.2021.105840.
8. Aripov A.N, Akhunjanova L.L, Khamroev T.T, Aripov Abdumalik Nigmatovich, Akhunjanova Lola Lazizovna, & Khamroev Tolmas Tolibovich. (2022). Differential

ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

Analysis of Chronic Toxic Hepatitis Caused by The Introduction of Heliotrin Solution in Various Ways. Texas Journal of Medical Science, 4, 58–62. Retrieved from https://zienjournals.com/index.php/tjms/article/view/670

9. Rashidov S.Z., Rakhimboev S.D., Sanoev Z.I., Abdinazarov I.T., Khamroev T.T., Ismailova D.S., & Elmuradov B.J.. (2022). Study of psychoactive activity potassium salt 5-(o-aminophenyl)-1,3,4- oxadiazole-2-thion (D-361). International Journal of Medical Sciences And Clinical Research, 2(09), 1–5. https://doi.org/10.37547/ijmscr/Volume02Issue09-01
10. Góralczyk-Bińkowska, A.; Szmajda-Krygier, D.; Kozłowska, E. The Microbiota–Gut–Brain Axis in Psychiatric Disorders. Int. J. Mol. Sci. 2022, 23, 11245.
11. Heiss C.N., Olofsson L.E. The Role of the Gut Microbiota in Development, Function and Disorders of the Central Nervous System and the Enteric Nervous System. J. Neuroendocrinol. 2019;31:e12684. doi: 10.1111/jne.12684.
12. Арипов А.Н., Арипов О.А., Ахунджанова Л.Л., Набиев А.Ў., Нишанбаев С.З., Набиева Д.А., Ҳамроев Т.Т. Тажриба шароитида сафорофлавонолозиднинг гепатотроп фаоллигини ўрганиш. Oriental Journal of Medicine and Pharmacology, 2(02), 55–64. https://doi.org/10.37547/supsci-ojmp-02-02-07
13. Angst D., Gessier F., Janser P., Vulpetti A., Wälchli R., Beerli C., et al. Discovery of LOU064 (Remibrutinib), a potent and highly selective covalent inhibitor of Bruton's Tyrosine Kinase. J. Med. Chem. 2020;63(10):5102–5118. doi: 10.1021/acs.jmedchem.9b01916.
14. Zakhidova L.T., Saidkhodjaeva D.M., Sanoev Z.I., Tukhtasheva V.F., Rakhmanova H.A.., Hamroyev T.T. Toxicological Characteristics Of N-Deacetyllappaconitine Under Chronic Administration In White Rats. The American Journal of Applied Sciences, 3(03), 34-41. https://doi.org/10.37547/tajas/Volume03Issue03-06
15. Guerra E., Garcia-Sanchez Y., Jornet-Gibert M., Nuñez J., Balaguer-Castro M., Madden K. Clinical practice guidelines: The good, the bad, and the ugly. Injury. 2022;54((Suppl. S3)):S26–S29. doi: 10.1016/j.injury.2022.01.047.
16. Khamroev T.T., Sanoev Z.I., Rakhimboev S.D., Abdinazarov I.T., Rashidov S.Z. Effect of antiarrhythmic substance N – dezacetyllapoconitin on the central nervous system. ISJ Theoretical &Applied Science, 07 (99), 153-157. http://soi.org/1.1/TAS-07-99-31 Doi:https://dx.doi.org/10.15863
17. Asahina Y., Wurtz N.R., Arakawa K., Carson N., Fujii K., Fukuchi K., et al. Discovery of BMS-986235/LAR-1219: a potent formyl peptide receptor 2 (FPR2) selective agonist for the prevention of heart failure. J. Med. Chem. 2020;63(17):9003–9019. doi: 10.1021/acs.jmedchem.9b02101.
18. Sanoev Z.I., Abdinazarov I.T., Rakhimboev S.D., Rashidov S.Z., Hamroyev T.T. Study Of The General Pharmacological Properties Of A New Antiarrhythmic N-Deacetyllappaconitine With Oral Administration. The American Journal of Medical Sciences and Pharmaceutical Research, 3(03), 60-64. https://doi.org/10.37547/TAJMSPR/Volume03Issue03-08
19. Patton E.E., Zon L.I., Langenau D.M. Zebrafish disease models in drug discovery: From preclinical modelling to clinical trials. Nat. Rev. Drug Discov. 2021;20:611–628. doi: 10.1038/s41573-021-00210-8.
20. Sanoev Z. I, Ismailova D. S, Rakhimboev S. D. O, Khamroev T, T, Elmuradov B. Z, Abdinazarov I. T, Rashidov S. Z. O. Synthesis and Research Anticonvulsant Activity of

Annulated Triazolo-Thiadiazine Derivative in Laboratory Animals. Biomed Pharmacol J 2023;16(4). DOI : https://dx.doi.org/10.13005/bpj/2820

21. Stokes, J.M.; Yang, K.; Swanson, K.; Jin, W.; Cubillos-Ruiz, A.; Donghia, N.M.; MacNair, C.R.; French, S.; Carfrae, L.A.; Bloom-Ackermann, Z. A deep learning approach to antibiotic discovery. Cell 2020, 180, 688–702.e613.
22. Sanoev, Z.I., Djaxangirov, F.N., Sadikov, A.Z., Sagdullaev, S.S. Hamroyev T.T. Antiarrhythmic activity of N-deacetyllappaconitine when administered orally. Annals of the Romanian Society for Cell Biology,2021,25(2), 2339–2346. https://doi.org/10.37547/tajas/Volume03Issue03-06
23. Thafar, M.A.; Alshahrani, M.; Albaradei, S.; Gojobori, T.; Essack, M.; Gao, X. Affinity2Vec: Drug-target binding affinity prediction through representation learning, graph mining, and machine learning. Sci. Rep. 2022, 12, 4751.
24. Sokhib Rashidov Zamon o‘g‘li, Muslimakhon Kamolova Mirzokhidjon qizi, Ikhvoliddin Mirzaev Komiljon o‘g‘li, Nodira Pardaeva Botir qizi, Sevara Rakhmatullaeva Shukhrat qizi/. (2025). The importance of cardiotonic drugs in medical practice, the range of applications and the advantages of their use. International Journal of Cognitive Neuroscience and Psychology, 3(5), 95–100. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1856
25. Frileux, S.; Boltri, M.; Doré, J.; Leboyer, M.; Roux, P. Cognition and Gut Microbiota in Schizophrenia Spectrum and Mood Disorders: A Systematic Review. Neurosci. Biobehav. Rev. 2024, 162, 105722.
26. Sanoev Zafar Isomiddinovich, Rashidov Sokhib Zamon ugli, Raximboev Sukhrob Davlatyor ugli, Abdinazarov Ibrokhim Tuychievich, Khamroev Tolmas Tolibovich, Ismailova Dilnoza Safaralievna, & Elmuradov Burkhon Juraevich. (2022). Research of Anticonvulsant Activity of Compound 5- (P-Aminophenyl) - 1,3,4-Oxadiazole-2-Thion. Texas Journal of Medical Science, 13, 17–21. Retrieved from https://zienjournals.com/index.php/tjms/article/view/2434
27. Ma X, Zhou S, Xu X, Du Q. Copper-containing nanoparticles: mechanism of antimicrobial effect and application in dentistry-a narrative review. Front Surg. 2022;9:905892. 10.3389/fsurg.2022.905892.
28. Yu. R. Mirzaev, T. T. Khamroev, E. M. Ruzimov, B. N. Khandamov, & Sh. M. Adizov. (2022). Evaluation of the Effect on the Nervous System of Substances with an Alkaloid Structure Having Antitumor Activity. Journal Healthcare Treatment Development(JHTD) ISSN : 2799-1148, 2(06), 6–10. Retrieved from http://journal.hmjournals.com/index.php/JHTD/article/view/1577
29. Kong Y.K., Song K.-S., Jung M.E., Kang M., Kim H.J., Kim M.J. Discovery of GCC5694A: A potent and selective sodium glucose co-transporter 2 inhibitor for the treatment of type 2 diabetes. Bioorg. Med. Chem. Lett. 2022;56 doi: 10.1016/j.bmcl.2021.128466.
30. Aripov A.N., Aripov O.A., Akhunjanova L.L., Nabiev A.O., Nabieva D.A., & Khamroev T.T. (2022). Study the antifibrous efficacy of plant proanthocyanidin in rats with chronic heliotrine liver damage. Frontline Medical Sciences and Pharmaceutical Journal, 2(05), 16–25. https://doi.org/10.37547/medical-fmspj-02-05-03.
31. Paul S, Hossain TJ, Ali F, Hossain ME, Chowdhury T, Faisal IK, et al. Assessment of the in-vitro probiotic efficacy and safety of Pediococcus pentosaceus L1 and Streptococcus thermophilus L3 isolated from laban, a popular fermented milk product. Arch Microbiol 2024;206. 10.1007/s00203-023-03812-5.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

32. Sokhib Rashidov Zamon o‘g‘li, Nilufar Ergasheva Ag’zamjon qizi, Elyor Zokirboyev Anvarjon o‘gli, Umidjon Akramov Abdusamad o‘g‘li, & Aziza Egamberdieva Farkhod qizi. (2025). Drugs That Increase the Tone of the Human Body and Pharmacological Characteristics of Immunodeficiency Agents. American Journal of Biomedicine and Pharmacy, 2(5), 300–306. Retrieved from https://biojournals.us/index.php/AJBP/article/view/1065
33. Günther J., Hillig R.C., Zimmermann K., Kaulfuss S., Lemos C., Nguyen D., et al. BAY-069, a Novel (Trifluoromethyl) pyrimidinedione-Based BCAT1/2 Inhibitor and Chemical Probe. J. Med. Chem. 2022;65(21):14366–14390. doi: 10.1021/acs.jmedchem.2c00441.
34. Sokhib Rashidov Zamon o‘g‘li, Murodjon Nabiev Mahammadkarim o‘g‘li, Mo'tabar Yoqubjonova Khusanboy qizi, Shakhzodakhon Bekmurodova Po‘latjon qizi, & Jumanazar To‘ychiev Saidqul o‘g‘li. (2025). Comparative Analysis of Drugs Used for Anemia and Drugs Storing Iron. Research Journal of Trauma and Disability Studies, 4(5), 190–195. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5141
35. Rosa J.G.S., Lima C., Lopes-Ferreira M. Zebrafish larvae behavior models as a tool for drug screenings and pre-clinical trials: A review. Int. J. Mol. Sci. 2022;23:6647. doi: 10.3390/ijms23126647.
36. Sokhib Rashidov Zamon o‘g‘li, Shakhzoda Abduraimova Abdusattor qizi, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, & Makhsuma Dovutkho’jayeva Maqsudjonovna. (2025). Classification, Indications for Use, Range of Applications and Disadvantages of Medicines against Nematodes and Leishmania. Research Journal of Trauma and Disability Studies, 4(5), 196–201. Retrieved from https://journals.academiczone.net/index.php/rjtds/article/view/5142
37. Mi R, Lu W, Zhang X, Yan F, Han B, et al. (2025) Screening and identification of strains for high quality and antioxidant activity of Baijiu from strong-flavor Daqu and analysis of microbial synergistic effects. PLOS ONE 20(3): e0319616. https://doi.org/10.1371/journal.pone.0319616
38. Sokhib Rashidov Zamon o‘g‘li, Nigora Yusufjonova Mirrakhim qizi, Diyora Turdibekova Erkinjon qizi, Makhsuma Dovutkho’jaeva Maqsudjonovna, Shakhzoda Abduraimova Abdusattor qizi, Analysis of the effect of medicines used in medical practice for various diseases on the fetus , european journal of modern medicine and practice: Vol. 5 No. 5 (2025) 342-347.
39. Marsit, N.M., Saadawi, S. & Alennabi, K. Challenges of growth-based microbiological methods in sterility assurance of pharmaceutical product manufacturing. Discov. Pharm. Sci. 1, 13 (2025). https://doi.org/10.1007/s44395-025-00020-6
40. Sokhib Rashidov Zamon o‘g‘li, Elyor Zokirboev Anvarjon ògli, Umidjon Akramov Abdusamad o‘g‘li, Aziza Egamberdiyeva Farkhod qizi, Munisa Qo‘shbekova Ro‘zimbek qizi. (2025). Analysis of general and specific pharmacological properties of fat-soluble vitamins. International Journal of Cognitive Neuroscience and Psychology, 3(5), 101–106. Retrieved from https://medicaljournals.eu/index.php/IJCNP/article/view/1857
41. Ali F, Silvy TN, Hossain TJ, Uddin MK, Uddin MS. Prevalence and antimicrobial resistance phenotypes of Salmonella species recovered at various stages of broiler operations in Hathazari, Bangladesh. Int J One Health. 2021;7(2):158–164. 10.14202/IJOH.2021.

AMERICAN ACADEMIC PUBLISHER
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
ISSN NUMBER: 2692 - 5206 Volume 6. No 03. March ,2026

42. Lima PG, Oliveira JT, Amaral JL, Freitas CD, Souza PF. Synthetic antimicrobial peptides: characteristics, design, and potential as alternative molecules to overcome microbial resistance. Life Sci. 2021;278:119647.
43. Mingming You, Nan Chen, Yuanyuan Yang, Lingjun Cheng, Hongzhang He, Yanhua Cai, Yating Liu, Haiyue Liu, Guolin Hong. The gut microbiota–brain axis in neurological disorders. MedCommVolume 5, Issue 8 e656. https://doi.org/10.1002/mco2.656